胺碘酮联合厄贝沙坦治疗慢性心力衰竭伴室性心律失常的临床效果  

Clinical effect of amiodarone combined with irbesartan in the treatment of chronic heart failure with ventricular arrhythmias

作　　者：李翠芝[1] 李景隆[1] LI Cuizhi;LI Jinglong(Department of Cardiovascular Medicine,Guangzhou Eighth People′s Hospital,Guangzhou510060,China)

机构地区：[1]广州市第八人民医院心血管内科,广东广州510060

出　　处：《中国现代医生》2022年第8期33-35,39,共4页China Modern Doctor

摘　　要：目的探讨对慢性心力衰竭伴室性心律失常患者给予胺碘酮联合厄贝沙坦治疗的价值。方法遵从“随机数字表法”分组,将广州市第八人民医院2019年1~12月100例慢性心力衰竭伴室性心律失常患者分为对照组(50例,胺碘酮常规治疗)和观察组(50例,胺碘酮联合厄贝沙坦治疗),比较两组治疗后的总有效率、心功能[包括6 min步行试验距离(6MWT)、左心室射血分数、左心室舒张末期内径(LVEDD)及左心室收缩末期内径(LVESD)]及心脏指数(CI)、N末端脑钠肽前体(NT-pro BNP)水平。结果观察组临床总有效率为96.00%,明显高于对照组的78.00%(P<0.05)。经治疗后,观察组左心室射血分数为(52.23±12.23)%,高于对照组的(44.25±10.23)%,观察组LVEDD、LVESD为(50.23±5.23)mm、(45.23±6.56)mm,明显低于对照组的(58.56±7.52)mm、(53.23±5.56)mm;观察组的6MWT为(362.98±24.50)m,比对照组的(312.65±25.14)m更长;经治疗后观察组患者CI、NT-pro BNP水平分别为(3.00±0.12)L/(min·m^(2))、(433.23±45.23)pg/ml,明显低于对照组的(3.41±0.55)L/(min·m^(2))、(599.56±44.12)pg/ml(P<0.05)。两组副反应情况比较,差异无统计学意义(P>0.05)。结论对慢性心衰伴室性心律失常开展药物治疗,建议采纳胺碘酮联合厄贝沙坦治疗方案,可有效提升临床疗效并改善心功能,用药安全性可靠。Objective To investigate the value of amiodarone combined with irbesartan in treating patients with chronic heart failure and ventricular arrhythmias.Methods According to the random number table method,100 patients with chronic heart failure and ventricular arrhythmias admitted to Guangzhou Eighth People′s Hospital from January 2019 to December 2019 were divided into the control group(50 cases,routine amiodarone treatment)and the observation group(50 cases,amiodarone combined with irbesartan treatment).The total effective rate,cardiac function[including 6 minute walk test(6MWT),left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)],cardiac index(CI)and N-terminal pro-brain natriuretic peptide(NT-pro BNP)level were compared between the two groups after treatment.Results The total effective rate in the observation group was as high as 96.00%,which was significantly higher than that of 78.00%in the control group(P<0.05).After treatment,LVEF in the observation group[(52.23±12.23%])was higher than that in the control group([44.25±10.23]%).LVEDD and LVESD([50.23±5.23]mm)and([45.23±6.56]mm)were significantly lower than those in the control group([58.56±7.52]mm)and([53.23±5.56]mm).The 6MWT in the observation group([362.98±24.50]m)was longer than that in the control group([312.65±25.14]m).After treatment,the CI and NT-pro BNP levels in the observation group were(3.00±0.12)L/(min·m^(2)),(433.23±45.23)pg/ml,which were significantly lower than those in the control group were(3.41±0.55)L/(min·m^(2)),(599.56±44.12)pg/ml(P<0.05).There was no significant difference in terms of the side effects between the two groups(P>0.05).Conclusion For patients with chronic heart failure and ventricular arrhythmias,it is recommended to adopt amiodarone combined with irbesartan treatment plan,which can effectively enhance the clinical efficacy and improve cardiac function with considerable medication safety.

关 键 词：胺碘酮 厄贝沙坦 慢性心力衰竭 室性心律失常 心功能 

分 类 号：R541.6[医药卫生—心血管疾病]